Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) – Jefferies Group raised their FY2016 earnings estimates for shares of Dicerna Pharmaceuticals in a research note issued on Thursday. Jefferies Group analyst E. Yang now expects that the firm will post earnings of ($3.32) per share for the year, up from their previous forecast of ($3.34). Jefferies Group also issued estimates for Dicerna Pharmaceuticals’ Q4 2016 earnings at ($0.94) EPS, FY2017 earnings at ($2.26) EPS, FY2018 earnings at ($1.98) EPS, FY2019 earnings at ($1.74) EPS and FY2020 earnings at ($1.73) EPS.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.75) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.84) by $0.09.

Several other analysts also recently weighed in on DRNA. Cowen and Company reissued a “buy” rating on shares of Dicerna Pharmaceuticals in a research note on Sunday, June 26th. Stifel Nicolaus lowered their price target on shares of Dicerna Pharmaceuticals from $16.00 to $13.00 and set a “buy” rating for the company in a research note on Thursday, June 30th. Chardan Capital decreased their price objective on shares of Dicerna Pharmaceuticals from $5.00 to $4.00 and set a “neutral” rating on the stock in a research report on Thursday, June 30th. Leerink Swann restated a “buy” rating on shares of Dicerna Pharmaceuticals in a research report on Thursday, June 30th. Finally, Zacks Investment Research cut shares of Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, August 25th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $12.30.

Dicerna Pharmaceuticals (NASDAQ:DRNA) opened at 4.59 on Monday. The company’s market cap is $95.26 million. Dicerna Pharmaceuticals has a 12 month low of $2.69 and a 12 month high of $15.93. The company has a 50-day moving average of $3.87 and a 200 day moving average of $3.91.

Several institutional investors have recently made changes to their positions in DRNA. State Street Corp boosted its position in shares of Dicerna Pharmaceuticals by 20.7% in the first quarter. State Street Corp now owns 209,015 shares of the biopharmaceutical company’s stock valued at $1,123,000 after buying an additional 35,820 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Dicerna Pharmaceuticals by 1.4% in the first quarter. Geode Capital Management LLC now owns 101,528 shares of the biopharmaceutical company’s stock valued at $544,000 after buying an additional 1,371 shares in the last quarter. Renaissance Technologies LLC bought a new position in shares of Dicerna Pharmaceuticals during the first quarter valued at about $160,000. Opus Point Partners Management LLC boosted its position in shares of Dicerna Pharmaceuticals by 8.0% in the first quarter. Opus Point Partners Management LLC now owns 108,000 shares of the biopharmaceutical company’s stock valued at $579,000 after buying an additional 8,000 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new position in shares of Dicerna Pharmaceuticals during the first quarter valued at about $343,000. Institutional investors own 62.38% of the company’s stock.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

5 Day Chart for NASDAQ:DRNA

Receive News & Stock Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.